Komboglyze (saxagliptin and metformin HCl)

Komboglyze (saxagliptin and metformin HCl) is an immediate release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with Type 2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets.

Co-developed and co-commercialised with BMS.